Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome)

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 183-193

  Buchanan, Daniel D ^a,b   Rosty, Christophe ^a,c,d   Clendenning, Mark ^a   Spurdle, Amanda B ^e   Win, Aung Ko ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Envoi Specialist Pathologists   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer risk; Germline mutation; Lynch syndrome; Screening; Somatic mutation

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6;

CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA METHYLATION; ENDOMETRIUM CANCER; EPCAM GENE; EXO1 GENE; GENE; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GENETIC EPIGENESIS; GENETIC RISK; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE DETECTION; HIGH RISK PATIENT; HUMAN; ITGA9 GENE; LRRFIP2 GENE; MISMATCH REPAIR; MLH1 GENE; MLH3 GENE; MOSAICISM; MSH2 GENE; MSH3 GENE; MSH6 GENE; PATIENT CARE; PMS1 GENE; PMS2 GENE; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 84908499880     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S48625     Document Type: Review

References (77)

1. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007; 21(20): 2525-2538.
2. Buchanan DD, Tan YY, Walsh MD, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol. 2014; 32(2): 90-100.
3. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009; 41(1): 112-117.
4. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96(4): 261-268.
5. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012; 30(9): 958-964.
6. Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2012; 104(18): 1363-1372.
7. Win AK, Lindor NM, Winship I, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013; 105(4): 274-279.
8. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011; 60(7): 950-957.
9. Win AK, Parry S, Parry B, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol. 2013; 20(6): 1829-1836.
10. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118(5): 829-834.
11. Win AK, Macinnis RJ, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013; 50(12): 785-793.
12. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005; 23(27): 6524-6532.
13. Jenkins MA, Dowty JG, Hopper JL, Southey MC. Molecular screening of all colorectal tumors diagnosed before age 50 years followed by genetic testing efficiently identifies Lynch syndrome cases. Int J Cancer. 2009; 124(5): x-xi.
14. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer. 2009; 124(5): 1097-1102.
15. Schofield L, Grieu F, Goldblatt J, Amanuel B, Iacopetta B. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours. Fam Cancer. 2012; 11(1): 1-6.
16. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010; 139(6): 2197. e1-e7.
17. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352(18): 1851-1860.
18. Piñol V, Castells A, Andreu M, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005; 293(16): 1986-1994.
19. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66(15): 7810-7817.
20. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008; 26(35): 5783-5788.
21. Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. Scand J Gastroenterol. 2011; 46(11): 1340-1348.
22. Moreira L, Balaguer F, Lindor N, et al; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012; 308(15): 1555-1565.
23. Lancaster JM, Powell CB, Kauff ND, et al; Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107(2): 159-162.
24. Tan YY, McGaughran J, Ferguson K, et al; ANECS Group. Improving identification of lynch syndrome patients: a comparison of research data with clinical records. Int J Cancer. 2013; 132(12): 2876-2883.
25. Clarke BA, Cooper K. Identifying lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol. 2012; 19(4): 231-238.
26. Moline J, Mahdi H, Yang B, et al. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol. 2013; 130(1): 121-126.
27. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998; 95(12): 6870-6875.
28. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012; 49(3): 151-157.
29. Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013; 31(10): 1336-1340.
30. Win AK, Lindor N, Jenkins M. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res. 2013; 15(2): R27.
31. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(3): 437-449.
32. Levine AJ, Win AK, Buchanan DD, et al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. Cancer Prev Res (Phila). 2012; 5(2): 328-335.
33. Win AK, Buchanan DD, Rosty C, et al. Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. Gut. Epub March 10, 2014.
34. Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013; 144(5): 926-932. e1; quiz e13-e14.
35. Antelo M, Milito D, Shia J, et al. High frequency of Lynch-like syndrome in early-onset non-familial colorectal cancer. 17th Annual Meeting of the CGA-ICC; October 6-8, 2013; Anaheim, CA.
36. Vaughn CP, Baker CL, Samowitz WS, Swensen JJ. The frequency of previously undetectable deletions involving 3′ Exons of the PMS2 gene. Genes Chromosomes Cancer. 2013; 52(1): 107-112.
37. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer #70 years. Gynecol Oncol. 2012; 125(2): 414-420.
38. Newcomb PA, Baron J, Cotterchio M, et al; Colon Cancer Family Registry. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(11): 2331-2343.
39. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999; 116(6): 1453-1456.
40. Overbeek LI, Kets CM, Hebeda KM, et al. Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. Br J Cancer. 2007; 96(10): 1605-1612.
41. Clendenning M, Buchanan DD, Walsh MD, et al. Mutation deep within an intron of MSH2 causes Lynch syndrome. Fam Cancer. 2011; 10(2): 297-301.
42. Morak M, Koehler U, Schackert HK, et al; German HNPCC consortium. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. J Med Genet. 2011; 48(8): 513-519.
43. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013; 34(3): 490-497.
44. Raptis S, Mrkonjic M, Green RC, et al. MLH1-93G. A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007; 99(6): 463-474.
45. Whiffin N, Broderick P, Lubbe SJ, et al. MLH1-93G. A is a risk factor for MSI colorectal cancer. Carcinogenesis. 2011; 32(8): 1157-1161.
46. Kwok CT, Vogelaar IP, van Zelst-Stams WA, et al. The MLH1 c.-27C. A and c. 85G. T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. Eur J Hum Genet. 2014; 22(5): 617-624.
47. Wilding JL, McGowan S, Liu Y, Bodmer WF. Replication error deficient and proficient colorectal cancer gene expression differences caused by 3′UTR polyT sequence deletions. Proc Natl Acad Sci U S A. 2010; 107(49): 21058-21063.
48. Mao G, Pan X, Gu L. Evidence that a mutation in the MLH1 3′-untranslated region confers a mutator phenotype and mismatch repair deficiency in patients with relapsed leukemia. J Biol Chem. 2008; 283(6): 3211-3216.
49. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010; 107(49): 21098-21103.
50. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15): 6982-6987.
51. Meyer C, Brieger A, Plotz G, et al. An interstitial deletion at 3p21. 3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family. Clin Cancer Res. 2009; 15(3): 762-769.
52. Wagner A, van der Klift H, Franken P, et al. A 10-Mb paracentric inversion of chromosome arm 2p inactivates MSH2 and is responsible for hereditary nonpolyposis colorectal cancer in a North-American kindred. Genes Chromosomes Cancer. 2002; 35(1): 49-57.
53. Chen JM. The 10-Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: re-annotation and mutational mechanisms. Genes Chromosomes Cancer. 2008; 47(6): 543-545.
54. Rhees J, Arnold M, Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer. 2014; 13(2): 219-225.
55. Clendenning M, Walsh MD, Gelpi JB, et al. Detection of large scale 3′ deletions in the PMS2 gene amongst Colon-CFR participants: have we been missing anything? Fam Cancer. 2013; 12(3): 563-566.
56. Loukola A, Vilkki S, Singh J, Launonen V, Aaltonen LA. Germline and somatic mutation analysis of MLH3 in MSI-positive colorectal cancer. Am J Pathol. 2000; 157(2): 347-352.
57. Wu Y, Berends MJ, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet. 2001; 29(2): 137-138.
58. Liu HX, Zhou XL, Liu T, et al. The role of hMLH3 in familial colorectal cancer. Cancer Res. 2003; 63(8): 1894-1899.
59. Taylor NP, Powell MA, Gibb RK, et al. MLH3 mutation in endometrial cancer. Cancer Res. 2006; 66(15): 7502-7508.
60. Plaschke J, Preussler M, Ziegler A, Schackert HK. Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability. Int J Colorectal Dis. 2012; 27(7): 911-919.
61. Niessen RC, Kleibeuker JH, Westers H, et al. PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer. 2009; 48(4): 322-329.
62. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2006; 5(4): 353-358.
63. Loconte DC, Patruno M, Lastella P, et al. A rare MSH2 mutation causes defective binding to hMSH6, normal hMSH2 staining, and loss of hMSH6 at advanced cancer stage. Hum Pathol. Epub June 30, 2014.
64. de Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004; 10(3): 972-980.
65. Mangold E, Pagenstecher C, Friedl W, et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol. 2005; 207(4): 385-395.
66. Clendenning M, Macrae FA, Walsh MD, et al. Absence of PMS2 mutations in colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression. Clin Genet. 2013; 83(6): 591-593.
67. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012; 14(4): 357-366.
68. Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002; 3(10): 748-758.
69. Pastrello C, Fornasarig M, Pin E, Berto E, Pivetta B, Viel A. Somatic mosaicism in a patient with Lynch syndrome. Am J Med Genet A. 2009; 149A(2): 212-215.
70. Sourrouille I, Coulet F, Lefevre JH, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer. 2013; 12(1): 27-33.
71. Zhang R, Qin W, Xu GL, Zeng FF, Li CX. A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis. 2012; 14(3): e80-e89.
72. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6): 2073-2087. e3.
73. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014; 146(3): 643-646. e8.
74. Shia J, Zhang L, Shike M, et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol. 2013; 26(1): 131-138.
75. Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 2005; 129(5): 1392-1399.
76. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn. 2011; 13(1): 93-99.
77. Nagasaka T, Rhees J, Kloor M, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res. 2010; 70(8): 3098-3108.